Citadel Advisors’s Endava DAVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$804K Buy
181,800
+37,700
+26% +$208K ﹤0.01% 8173
2025
Q4
$911K Buy
144,100
+104,800
+267% +$802K ﹤0.01% 7601
2025
Q3
$358K Buy
39,300
+100
+0.3% +$1.25K ﹤0.01% 9944
2025
Q2
$601K Sell
39,200
-8,700
-18% -$147K ﹤0.01% 8206
2025
Q1
$935K Buy
47,900
+21,900
+84% +$608K ﹤0.01% 7106
2024
Q4
$803K Sell
26,000
-5,000
-16% -$137K ﹤0.01% 7498
2024
Q3
$792K Sell
31,000
-12,300
-28% -$369K ﹤0.01% 7321
2024
Q2
$1.27M Buy
43,300
+20,000
+86% +$593K ﹤0.01% 6146
2024
Q1
$886K Buy
23,300
+3,000
+15% +$180K ﹤0.01% 7162
2023
Q4
$1.58M Sell
20,300
-8,600
-30% -$532K ﹤0.01% 5792
2023
Q3
$1.66M Buy
28,900
+15,200
+111% +$793K ﹤0.01% 5554
2023
Q2
$710K Sell
13,700
-2,400
-15% -$129K ﹤0.01% 7169
2023
Q1
$1.08M Buy
16,100
+5,700
+55% +$448K ﹤0.01% 6600
2022
Q4
$796K Sell
10,400
-21,900
-68% -$1.63M ﹤0.01% 7266
2022
Q3
$2.6M Buy
32,300
+10,100
+45% +$959K ﹤0.01% 5092
2022
Q2
$1.96M Sell
22,200
-3,900
-15% -$408K ﹤0.01% 5584
2022
Q1
$3.47M Sell
26,100
-10,700
-29% -$1.35M ﹤0.01% 4886
2021
Q4
$6.18M Buy
36,800
+300
+0.8% +$46.5K ﹤0.01% 3920
2021
Q3
$4.96M Buy
+36,500
New +$4.71M ﹤0.01% 4315

Other funds holding DAVA

Citadel Advisors's DAVA Position: Q4 2025 in Review

Citadel Advisors sold out of Endava (DAVA) in Q4 2025, closing a stake of 389,269 shares — an estimated $2.98M sold.

Citadel Advisors first reported a position in DAVA in Q3 2018 and held it in 26 quarters. The position peaked at $30.1M in Q3 2022. 101 funds tracked by Wall St. Rank hold DAVA as of Q4 2025.

  • Citadel Advisors reported no remaining Endava position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 389,269 Endava shares in Q4 2025, an estimated $2.98M.
  • Citadel Advisors first reported a position in Endava in Q3 2018 and held it in 26 quarters.
  • Citadel Advisors's Endava position peaked at $30.1M in Q3 2022.
  • 101 funds tracked by Wall St. Rank held Endava as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.